Zhaoyan New Pharmaceutical (603127.SH) released its 2023 annual report, achieving operating revenue of 2,376 billion yuan,...
According to the Zhitong Finance App, Zhaoyan New Pharmaceutical (603127.SH) released its 2023 annual report, achieving revenue of 2,376 billion yuan, an increase of 4.78% over the previous year. Net profit attributable to shareholders of listed companies was 397 million yuan, a year-on-year decrease of 63.04%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 338 million yuan, a year-on-year decrease of 66.89%. A cash dividend of 1.6 yuan (tax included) is distributed to all shareholders for every 10 shares.
The company's net profit, which is attributable to shareholders of listed companies after deducting non-recurring profit and loss, is mainly due to the combined effects of laboratory service business profits and fund management income, as well as fluctuations in the market price of biological assets.